Americans Can Save $6,000 on This Drug

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Published
Americans Can Save $6,000 on This Drug

© BackyardProduction / iStock via Getty Images

Prescription drug prices in America are extraordinarily high. According to the Rand Corporation, drug prices are 2.56 times higher than in other nations. There is a simple reason. Andrew Mulcahy, a senior health policy researcher at Rand, commented on the data: “Brand-name drugs are the primary driver of the higher prescription drug prices in the United States.”

President Biden plans to partially remedy the problem. This would include allowing Medicare to negotiate prices. However, that may not have much of an effect on drug prices until 2025. Biden framed the issue this way: “It’s safe to say that all of us can agree that prescription drugs are outrageously expensive in this country.” It was an acknowledgment of the fact that many Americans cannot afford the drugs they need to treat a wide variety of medical conditions.

High tech companies have started to offer solutions. Some use systems that collect data from tens of thousands of pharmacies to steer people in the direction of the lowest prices. Others allow people to report what they have paid so that the information can be shared with others.

One of the latest attempts to lower drug prices uses very little technology. One of America’s richest people has set up a system to sell expensive drugs at large discounts. Mark Cuban Cost Plus Drug Company was launched on January 19. According to Becker’s Hospital Review it “produces low-cost versions of high-cost generic drugs.” Becker’s identified 27 drugs with savings of over $100 based on this system. There are discounts available on hundreds of drugs.
[nativounit]
The drug with the biggest price cut is albendazole (generic for Albenza), which comes in tablet form. The retail price for the drug is $6,565.20. The program cuts this by $6,112.28 to $453.

Albendazole is an antiworm medicine that, according to Drug.com, “prevents newly hatched insect larvae (worms) from growing or multiplying in your body.” Among its side effects is a risk to unborn children. It also can cause headaches, fever and nausea.

Click here to see which drugs Americans are running short on.
[wallst_email_signup]

Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Continue Reading

Top Gaining Stocks

ENPH Vol: 11,276,116
UAL Vol: 9,038,519
SMCI Vol: 38,283,266
DAL Vol: 11,954,617
CCL Vol: 51,734,642

Top Losing Stocks

HAS Vol: 5,639,801
CTRA Vol: 73,319,495
CME Vol: 2,860,171
INTU Vol: 6,992,567
ADI Vol: 10,352,898